Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies

Saleki, Kiarash; Yaribash, Shakila; Banazadeh, Mohammad; Hajihosseinlou, Ehsan; Gouravani, Mahdi; Saghazadeh, Amene; Rezaei, Nima

doi:10.1016/j.ejphar.2021.174248

Cited by 31 publications

(26 citation statements)

References 150 publications

(659 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specifically, infection with the SARS virus can lead to a weakness of the immune tolerance to some antigens in lung tissue and the production of autoantibodies, resulting in severe lung tissue damage (14). Additionally, there is evidence hormonotherapy applied in SARS treatment not only contributes to the enhancement of autoimmune tolerance of patients, but also leads to a shorter duration of hospital stay (15). In the present study, a similar effect was found in that the length of stay in hospital of patients with COVID-19 who underwent hormonotherapy was reduced.…”

Section: Discussionsupporting

confidence: 82%

Efficacy and safety of glucocorticoids in treatment of COVID-19: a retrospective study

Fei¹,

Gao²,

Zhang³

et al. 2022

Ann Palliat Med

View full text Add to dashboard Cite

Background: Novel coronavirus pneumonia is a novel kind of highly contagious disease without any specific drugs. Considering the successful experience of antiviral therapy combined with glucocorticoids (GCs) in severe acute respiratory syndrome, this study was designed to evaluate the clinical efficacy of GCs in treating patients with coronavirus disease 2019 (COVID-19).Methods: A cohort of 42 patients with COVID-19 admitted to The First Hospital of Jiaxing from January 4, 2020, to February 16, 2020, were included and grouped into a test group (n=20) and control group (n=22) based on their therapeutic regimens. There were no significant differences in baseline characteristics between patients in the two groups. Conventional treatment (antiviral therapy) was given to patients in both groups, while an additional hormone drug (GCs) was used in patients in the test group. Indices including body temperature, blood routine indices [white blood cell (WBC), lymphocyte, monocyte, and C-reactive protein (CRP)], blood biochemical indices [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)], and complications were recorded during the treatment. Time to achieve negative virus nucleic acid (nCoV-RNA) testing, and hospital stays were also observed and compared between the two groups.Results: All included patients completed the trial. After treatment, superior therapeutic efficacy was achieved in patients in the test group, with body temperature dropping more significantly with a much shorter recovery time compared to the control group (P=0.0412). Simultaneously, the percentage of patients with abnormal blood routine indices (WBC), monocyte, and (CRP) in the test group was reduced more sharply, while no noticeable difference was observed in the number of patients who developed abnormal blood biochemical indices during treatment between the two groups. Additionally, a shorter duration of hospital stays was found in the test group relative to the control group (14.84±8.76 vs. 18.25±7.42 days, P>0.05). Patients who received GCs had a shorter recovery time for body temperature and inflammation.Conclusions: Hormonotherapy with GCs can accelerate the recovery time for body temperature as well as inflammation in patients with COVID-19. It deserves promotion and application in the clinical treatment of coronavirus disease as a form of adjuvant medicine. The ongoing focus of research is on long-term adverse events in GCs.

show abstract

Section: Discussionsupporting

confidence: 82%

Efficacy and safety of glucocorticoids in treatment of COVID-19: a retrospective study

Fei¹,

Gao²,

Zhang³

et al. 2022

Ann Palliat Med

View full text Add to dashboard Cite

show abstract

“…Among various human CoVs, SARS‐CoV‐2 caused a severe mortality rate close to 1.38, and the most common symptoms in positive cases were cough, fever, headache, fatigue, diarrhea, and blood‐stained mucous. In the current scenario, the characterization of novel biomarkers which may play an important role in prediction and observation in the status of SARS‐CoV‐2 disease is required 13,14 . (p. 2)…”

Section: Introductionmentioning

confidence: 99%

“…In the current scenario, the characterization of novel biomarkers which may play an important role in prediction and observation in the status of SARS‐CoV‐2 disease is required. 13 , 14 (p. 2)…”

Section: Introductionmentioning

confidence: 99%

Integrative multiomics and in silico analysis revealed the role of ARHGEF1 and its screened antagonist in mild and severe COVID‐19 patients

Jha

Singh

Arora

et al. 2022

J of Cellular Biochemistry

View full text Add to dashboard Cite

COVID-19 is a sneaking deadly disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The rapid increase in the number of infected patients worldwide enhances the exigency for medicines. However, precise therapeutic drugs are not available for COVID-19; thus, exhaustive research is critically required to unscramble the pathogenic tools and probable therapeutic targets for the development of effective therapy. This study utilizes a chemogenomics strategy, including computational tools for the identification of viralassociated differentially expressed genes (DEGs), and molecular docking of potential chemical compounds available in antiviral, anticancer, and natural productbased libraries against these DEGs. We scrutinized the messenger RNA expression profile of SARS-CoV-2 patients, publicly available on the National Center for Biotechnology Information-Gene Expression Omnibus database, stratified them into different groups based on the severity of infection, superseded by identification of overlapping mild and severe infectious (MSI)-DEGs. The profoundly expressed MSI-DEGs were then subjected to trait-linked weighted co-expression network construction and hub module detection. The hub module MSI-DEGs were then exposed to enrichment (gene ontology + pathway) and protein-protein interaction network analyses where Rho guanine nucleotide exchange factor 1 (ARHGEF1) gene conjectured in all groups and could be a probable target of therapy. Finally, we used the molecular docking and molecular dynamics method to identify inherent

show abstract

“…Conversely, inborn defects in the IFN system or auto-antibodies against type I IFNs are frequently associated with severe disease [10,11]. Thus, IFN is currently evaluated in clinical trials as a therapeutic approach [20].…”

Section: Introductionmentioning

confidence: 99%

The Delta variant of SARS-CoV-2 maintains high sensitivity to interferons in human lung cells

Nchioua¹,

Schundner

Klute³

et al. 2021

Preprint

View full text Add to dashboard Cite

Interferons are a major part of the anti-viral innate defense system. Successful pathogens, including the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), need to overcome these defenses to establish an infection. Early induction of interferons (IFNs) protects against severe coronavirus disease 2019 (COVID-19). In line with this, SARS-CoV-2 is inhibited by IFNs in vitro, and IFN-based therapies against COVID-19 are investigated in clinical trials. However, SARS-CoV-2 continues to adapt to the human population resulting in the emergence of variants characterized by increased transmission fitness and/or decreased sensitivity to preventive or therapeutic measures. It has been suggested that the efficient spread of these so-called “Variants of Concern” (VOCs) may also involve reduced sensitivity to IFNs. Here, we examined whether the four current VOCs (Alpha, Beta, Gamma and Delta) differ in replication efficiency or IFN sensitivity from an early isolate of SARS-CoV-2. All viruses replicated in a human lung cell line and in iPSC-derived alveolar type II cells (iAT2). The Delta variant showed accelerated replication kinetics and higher infectious virus production compared to the early 2020 isolate. Replication of all SARS-CoV-2 VOCs was reduced in the presence of exogenous type I, II and III IFNs. On average, the Alpha variant was the least susceptible to IFNs and the Alpha, Beta and Gamma variants show increased resistance against type III IFN. Although the Delta variant has outcompeted all other variants in humans it remained as sensitive to IFNs as an early 2020 SARS-CoV-2 isolate. This suggests that increased replication fitness rather than IFN resistance may be a reason for its dominance. Our results may help to understand changes in innate immune susceptibility of VOCs, and inform clinical trials exploring IFN-based COVID-19 therapies.

show abstract

Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies

Cited by 31 publications

References 150 publications

Efficacy and safety of glucocorticoids in treatment of COVID-19: a retrospective study

Efficacy and safety of glucocorticoids in treatment of COVID-19: a retrospective study

Integrative multiomics and in silico analysis revealed the role of ARHGEF1 and its screened antagonist in mild and severe COVID‐19 patients

The Delta variant of SARS-CoV-2 maintains high sensitivity to interferons in human lung cells

Contact Info

Product

Resources

About